← Back to Search

Cannabinoid

THC for HIV

Phase 1
Recruiting
Led By Deepak C D'Souza, MD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the ravlt will be administered prior to study drug administration at approximately 25 minutes after study drug administration.
Awards & highlights
No Placebo-Only Group

Summary

This trial will study the effects of THC on HIV-infected and uninfected cells.

Who is the study for?
This trial is for adults with or without HIV. Participants must be in good health, have no recent drug use (including cannabis), and show good adherence to medications if HIV-positive. They should pass a physical exam, psychiatric interview, lab tests, ECG, and vital signs check.
What is being tested?
The study is testing how Delta-9-THC affects the immune system's genetic activity and cytokine production differently in people with and without HIV. It explores whether THC can cause changes through epigenetic mechanisms.
What are the potential side effects?
While not explicitly listed here, potential side effects of Delta-9-THC may include altered mental state, dizziness, dry mouth, changes in heart rate or blood pressure among others.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the ravlt will be administered prior to study drug administration at approximately 25 minutes after study drug administration.
This trial's timeline: 3 weeks for screening, Varies for treatment, and the ravlt will be administered prior to study drug administration at approximately 25 minutes after study drug administration. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Cytokine Profile
Change in Cytokine Profile by THC between HIV-positive and HIV-negative Groups
Change in Gene Expression Alteration
+1 more
Secondary study objectives
Cannabinoid Relevant Molecules
Cannabis Subjective Effects
Change in total immediate recall on the RAVLT.
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Active Delta-9-THCExperimental Treatment1 Intervention
Active Delta-9-THC (0.03 mg/kg) administered intravenously.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Active Delta-9-THC
2015
Completed Phase 1
~60

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,930 Previous Clinical Trials
3,033,418 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,606 Previous Clinical Trials
3,329,829 Total Patients Enrolled
Deepak C D'Souza, MDPrincipal InvestigatorYale University Professor of Psychiatry
5 Previous Clinical Trials
507 Total Patients Enrolled

Media Library

Delta-9-THC (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT04920539 — Phase 1
Human Immunodeficiency Virus Infection Research Study Groups: Active Delta-9-THC
Human Immunodeficiency Virus Infection Clinical Trial 2023: Delta-9-THC Highlights & Side Effects. Trial Name: NCT04920539 — Phase 1
Delta-9-THC (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04920539 — Phase 1
~6 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top